{"title":"Antibiotic prophylaxis for prevention of bacterial endocarditis and infections of major joint prostheses [corrected].","authors":"J W Little","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The current trend in antibiotic prophylaxis for prevention of endocarditis is toward more simple, effective regimens to promote better patient and dentist compliance. All national medical groups are now recommending oral regimens for all at-risk patients, and most of these groups recommend single-dose oral regimens. The Swiss Working Group recommends multiple-dose amoxicillin for high-risk patients. The American Heart Association recommends two-dose oral regimens for all at-risk patients. Clindamycin appears to be the second drug of choice. The many pharmacokinetically different erythromycin preparations and the high rate of intolerance to many of these preparations has led to this change. No national or international medical groups recommended prophylaxis for patients with prosthetic joints. Most reviews conclude that there is little or no scientific evidence to support this use. It is time to stop the practice of prophylaxis for patients with prosthetic joints. The only patients with joint prostheses who should even be considered for prophylaxis are those patients considered at \"high\" risk.</p>","PeriodicalId":10853,"journal":{"name":"Current opinion in dentistry","volume":"2 ","pages":"93-101"},"PeriodicalIF":0.0000,"publicationDate":"1992-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in dentistry","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The current trend in antibiotic prophylaxis for prevention of endocarditis is toward more simple, effective regimens to promote better patient and dentist compliance. All national medical groups are now recommending oral regimens for all at-risk patients, and most of these groups recommend single-dose oral regimens. The Swiss Working Group recommends multiple-dose amoxicillin for high-risk patients. The American Heart Association recommends two-dose oral regimens for all at-risk patients. Clindamycin appears to be the second drug of choice. The many pharmacokinetically different erythromycin preparations and the high rate of intolerance to many of these preparations has led to this change. No national or international medical groups recommended prophylaxis for patients with prosthetic joints. Most reviews conclude that there is little or no scientific evidence to support this use. It is time to stop the practice of prophylaxis for patients with prosthetic joints. The only patients with joint prostheses who should even be considered for prophylaxis are those patients considered at "high" risk.